Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The approval makes Talzenna (talazoparib) the third PARP-blocking drug to be cleared by the FDA to treat prostate cancer.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
PARP inhibitor delays disease progression for patients with harmful BRCA and related mutations.
More than 40% of people treated with the PARP inhibitor saw tumor shrinkage.
The PARP inhibitor delayed disease progression by 20 months compared with a placebo.
It’s possible to identify these individuals in advance, helping them to focus on clinical trials of more effective treatments.
PARP inhibitor delays disease progression when used after successful chemotherapy.
First targeted therapy may prolong survival of men with advanced prostate cancer.
The three studies tested Zejula, Lynparza and veliparib in women with newly diagnosed advanced ovarian cancer.
Gaby Kressly, now in her early 80s, was diagnosed with ovarian cancer in 2016.
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.